Probiotic - March 2022 - 1 pill
Natural health product licensed in Canada
- Other names
- Probiotic
- Licence holder
- Xyngular Corporation
- NPN or DIN-HM
- 80118067
- Status
- Active licence
- Licence date
- 21 April 2022
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Lactobacillus acidophilus Source : Lactobacillus acidophilus - Cellule entière | 200 Millions d'UFC | Not calculated |
| Lactobacillus acidophilus Source : Lactobacillus acidophilus - Cellule entière | 1 mg | Not calculated |
| Lactiplantibacillus Plantarum Source : Lactiplantibacillus Plantarum - Cellule entière | 28.8 Milliards d'UFC | Not calculated |
| Lactiplantibacillus Plantarum Source : Lactiplantibacillus Plantarum - Cellule entière | 134.25 mg | Not calculated |
| Pediococcus acidilactici Source : Pediococcus acidilactici - Whole Cell | 17 mg | Not calculated |
| Pediococcus acidilactici Source : Pediococcus acidilactici - Whole Cell | 1.7 Milliards d'UFC | Not calculated |
| Bifidobacterium breve Source : Bifidobacterium breve - Cellule entière | 30 mg | Not calculated |
| Bifidobacterium breve Source : Bifidobacterium breve - Cellule entière | 3 Milliards d'UFC | Not calculated |
| Bifidobacterium animalis subsp. lactis | 800 Millions d'UFC | Not calculated |
| Bifidobacterium animalis subsp. lactis | 2 mg | Not calculated |
| Lacticaseibacillus Rhamnosus GG | 1 mg | Not calculated |
| Lacticaseibacillus Rhamnosus GG | 350 Millions d'UFC | Not calculated |
| Bifidobacterium longum subsp. longum Source : Bifidobacterium longum subsp. longum - Cellule entière | 100 Millions d'UFC | Not calculated |
| Bifidobacterium longum subsp. longum Source : Bifidobacterium longum subsp. longum - Cellule entière | 1 mg | Not calculated |
| Limosilactobacillus fermentum | 1 mg | Not calculated |
| Limosilactobacillus fermentum | 100 Millions d'UFC | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Dioxyde de silicium, Fruit de Baobab, Hypromellose, Poudre de racine de betterave, Gomme arabique (acacia), L-Leucine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 1 day |
Uses authorised in Canada
Text supplied in English because no French text is available.
Could promote a favorable gut flora. Helps support intestinal/gastrointestinal health. Source of Probiotics.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80118067
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.